Ibrunib 140 mg (Ibrutinib) Capsule

Ibrunib 140 (Ibrutinib) is a targeted anticancer medicine used in the treatment of specific blood cancers and immune-related conditions. It helps slow the growth and spread of abnormal B-cells by blocking Bruton's Tyrosine Kinase (BTK), an important protein involved in cancer cell survival.

Indicated for:

• Chronic Lymphocytic Leukemia (CLL)
• Small Lymphocytic Lymphoma (SLL)
• Mantle Cell Lymphoma (MCL)
• Waldenström Macroglobulinemia (WM)
• Marginal Zone Lymphoma (MZL)
• Chronic Graft-versus-Host Disease (cGVHD) in eligible patients

Generic Name: Ibrutinib

Active Ingredient:

• Ibrutinib 140 mg

Dosage Form:

• Capsule

Pharmacological Class:

• Bruton's Tyrosine Kinase (BTK) Inhibitor

Ibrutinib works by selectively inhibiting BTK, a key enzyme involved in the growth and survival of malignant B-cells.

The dosage of Ibrunib 140 should be determined by a qualified healthcare professional based on the patient's condition, treatment response, and overall health status.

General Administration Guidelines:

• Take orally once daily at the same time each day.
• Swallow the capsule whole with water.
• Do not crush, chew, or open the capsule.
• Can be taken with or without food.
• Continue treatment as directed by the treating physician.
• If a dose is missed, take it as soon as remembered on the same day. Do not take an extra dose to make up for a missed dose.

Important: Dosage may vary depending on the specific disease being treated and individual patient requirements. Always follow the prescribing physician's instructions.